These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effects of amrinone on myocardial energetics in severe congestive heart failure. Baim DS Am J Cardiol; 1985 Jul; 56(3):16B-18B. PubMed ID: 3161318 [TBL] [Abstract][Full Text] [Related]
27. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022 [TBL] [Abstract][Full Text] [Related]
28. [Positive inotropic agents. Generalities and classification]. Vahanian A; Le Potier J; Sergent J; Michel PL; Acar J Ann Med Interne (Paris); 1985; 136(3):242-6. PubMed ID: 2862822 [TBL] [Abstract][Full Text] [Related]
29. [Hemodynamic effects of various doses of a new inotropic: amrinoma]. Cárdenas M; Vidaurri A Arch Inst Cardiol Mex; 1979; 49(5):961-8. PubMed ID: 122781 [TBL] [Abstract][Full Text] [Related]
30. Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. Rude RE; Turi Z; Brown EJ; Lorell BH; Colucci WS; Mudge GH; Taylor CR; Grossman W Circulation; 1981 Jul; 64(1):139-45. PubMed ID: 7237712 [TBL] [Abstract][Full Text] [Related]
31. Left ventricular geometry, myocardial function and energetics of the dilated left ventricle. Influence of vasodilators and positive inotropic substances. Holubarsch C; Hasenfuss G; Thierfelder L; Just H Herz; 1991 Sep; 16 Spec No 1():298-303. PubMed ID: 1820296 [TBL] [Abstract][Full Text] [Related]
32. [Right ventricular hemodynamics and lung function following amrinone injection]. Klepzig M; Baur X; Hauser F; Mernitz G; Fruhmann G; Strauer BE Z Kardiol; 1984 Oct; 73(10):623-7. PubMed ID: 6516514 [TBL] [Abstract][Full Text] [Related]
33. Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure. Holubarsch C; Hasenfuss G; Thierfelder L; Just H Basic Res Cardiol; 1991; 86 Suppl 1():107-12. PubMed ID: 1827977 [TBL] [Abstract][Full Text] [Related]
34. A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure. Kanda H; Yokota M; Ishihara H; Nagata K; Kato R; Sobue T Am Heart J; 1996 Aug; 132(2 Pt 1):361-8. PubMed ID: 8701899 [TBL] [Abstract][Full Text] [Related]
35. Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts. Miller RR; Palomo AR; Brandon TA; Hartley CJ; Quinones MA Am Heart J; 1981 Sep; 102(3 Pt 2):500-8. PubMed ID: 7023220 [TBL] [Abstract][Full Text] [Related]
37. Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. Packer M; Medina N; Yushak M Am J Cardiol; 1984 Nov; 54(8):1025-9. PubMed ID: 6496324 [TBL] [Abstract][Full Text] [Related]
38. New positive inotropic agents for congestive heart failure. N Engl J Med; 1986 Aug; 315(6):396-7. PubMed ID: 3736614 [No Abstract] [Full Text] [Related]
40. Amrinone in the management of low cardiac output after open heart surgery. Goenen M; Pedemonte O; Baele P; Col J Am J Cardiol; 1985 Jul; 56(3):33B-38B. PubMed ID: 4025158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]